MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
<p>Abstract</p> <p>Background</p> <p>The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O<sup>6</sup>-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. Our propose is to analyze the prognostic si...
Na minha lista:
| Principais autores: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2012-12-01
|
| Serier: | Journal of Translational Medicine |
| Fag: | |
| Online adgang: | http://www.translational-medicine.com/content/10/1/250 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
